Vimarsana
Biggest News Aggregation in the World

Page 8 - Analyst Event News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analyst Event. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analyst Event Today - Breaking & Trending Today

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update - Vimarsana News

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript - Vimarsana News

Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript

NKTR earnings call for the period ending September 30, 2021.

Source: fool.com
ProQR Announces Third Quarter 2021 Operating and Financial Results - Vimarsana News

ProQR Announces Third Quarter 2021 Operating and Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights - Vimarsana News

Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates - Vimarsana News

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Read full article Oops! SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update : Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date 2021 a...

Source: yahoo.com